We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,330

Global privacy & data security update vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


Global Privacy & Cybersecurity Update Vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


The Demise of Valeant Pharmaceuticals: A Case Study in Rotten Culture and Business Ethics
  • Volkov Law Group
  • USA
  • April 3 2016

Showing my age again, Woody Allen’s Take the Money and Run included a hilarious scene when Woody’s parents wearing Groucho Marx glasses talk about


eCommerce Regulation, Bitcoin, Anti-Money Laundering, Shadow Insurance, 401(k) Litigation Expect Focus - Vol. IV, Fall 2015
  • Carlton Fields
  • USA
  • December 23 2015

On January 1, 2016, Section 38.6 of the California Insurance Code will take effect permitting consumers to conduct certain life, disability, and


Corporate Crime & Investigations Update - 11 January 2016
  • Addleshaw Goddard LLP
  • Ukraine, United Kingdom, USA
  • January 11 2016

Southwark Crown Court ordered Smith and Ouzman Ltd. to pay a total of approximately £2.2 million in relation to bribes paid to public officials for


Prevailing in an Era of Regulatory Enforcement - Balancing Risk and Compliance Expect Focus - Vol. II, July 2016
  • Carlton Fields
  • USA
  • June 30 2016

We previously warned that some individuals involved with arranging EB-5 investments may be required to register as broker-dealers (see “Immigrant


Advice of counsel defense in US v. Lauren Stevens: dismissal of indictment is not necessarily good news for companies
  • Hogan Lovells
  • USA
  • March 25 2011

The indictment last November of former GlaxoSmithKline (GSK) in-house counsel, Lauren Stevens, for purportedly obstructing a U.S. Food and Drug Administration (FDA) investigation into whether GSK marketed Wellbutrin, an anti-depressant drug, off-label, falsifying and concealing documents, and making false statements sent shockwaves through the legal community


Responding to a government subpoena or other document demand - six helpful hints
  • Ober Kaler
  • USA
  • December 31 2013

Presented by Gina L. Simms and James P. Holloway of OberKaler's Government Investigations and White Collar Defense Group, this podcast provides


D.C. Circuit decision in Friedman v. Sebelius overturns exclusions of three Purdue pharma executives
  • Sidley Austin LLP
  • USA
  • August 6 2012

In the pharmaceutical industry, government investigations initiated by whistleblower qui tam complaints canand often doresult in both civil and criminal charges against the company


U.S. v. Stevens: former GSK attorney acquitted on all counts
  • Ropes & Gray LLP
  • USA
  • May 16 2011

On May 10, 2011, Judge Roger Titus of the District of Maryland dismissed the case United States v. Stevens